Many patients with cancer receive antithrombotic medication. These drugs reduce the ability of the blood to clot, thereby reducing the risk of thrombosis. However, they can also have substantial negative side effects, such as bleeding and the associated reduced quality of life. Despite these side effects, antithrombotic medication is only rarely discontinued during the last stage of life. This is due to the lack of scientific evidence, but also simply because both physicians and patients find it hard to openly discuss death and dying.
SERENITY aims to make it easier for patients and their physicians to speak openly about the discontinuation of antithrombotic medication during the last stage of life with the aid of a dedicated online app. The app uses questions to start the conversation between physician and patient, and assesses the patient’s individual risk of bleeding and thrombosis. By taking into account factors such as gender, tumor type, and past thrombosis / bleeding history, the app makes it possible to tailor such questions to each individual patient. Importantly, the app does not give any advice, but merely makes discontinuing medication negotiable. The final decision lies with the patient, giving them more control over their own disease process, and within the context of their own personal preferences and values.
- Cardiff University
- Centre Hospitalier Universitaire de Saint-Etienne (France)
- University Medical Center Utrecht (Netherlands)
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz (Germany)
- Assistance Publique Hopitaux de Paris (France)
- Hospital Clinic de Barcelona (Spain)
- Centrum Medyczne Ksztalcenia Podyplomowego (Poland)
- S.A.M.O.T. Ragusa Onlus (Italy)
- Todaytomorrow (Netherlands)
- Aalborg University Hospital (Denmark)
- University of Hull (United Kingdom)
- Erasmus University Medical Center (Netherlands)
- Association Francophone des Soins Oncologiques de Support (France)
Horizon Europe | HORIZON-HLTH-2021-DISEASE-04-01, Improved supportive, palliative, survivorship and end-of-life care of cancer patients
- € 4,483,530.50
Follow us on LinkedIn for the latest successes!